Certain identified information has been excluded from the exhibit because it is both not material and is the type that the Registrant treats as private or confidential. Triple asterisks [***] denote exclusions. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 5th, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (the “Agreement”) is entered into as of November 30, 2023 (the “Execution Date”) by and between Skye Bioscience, Inc., a Nevada corporation, with an address of 11250 El Camino Real, Suite 100, San Diego, California, USA (“Skye”), and Tautomer Bioscience (Pty) Limited, a South African company with registered number 2016/450174/07 with an address of Woodmead North Office, 54 Maxwell Drive, Block B, Woodmead, 2191, Gauteng Province, South Africa (“Tautomer”). Skye and Tautomer are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
OFFER TO SELL UNIT 104 – 9295 198TH STREET LANGLEY, BCSell • December 5th, 2023 • Skye Bioscience, Inc. • Pharmaceutical preparations
We the undersigned hereby offer to sell the property municipally described as Unit 104 – 9295 198th Street, Langley BC having a legal description and more particularly known as:
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of AfricaSkye Bioscience, Inc. • December 5th, 2023 • Pharmaceutical preparations
SAN DIEGO, CA, and JOHANNESBURG, SOUTH AFRICA, December 5, 2023 -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing drugs targeting the endocannabinoid system, and Tautomer Bioscience (Pty) Limited (“Tautomer”), a privately-owned biopharmaceutical company focused on addressing unmet medical needs in oncology, pain management and infectious diseases, announced today that they have entered into an agreement under which Skye is providing Tautomer with an exclusive license to develop and commercialize Skye’s proprietary THC prodrug, SBI-100, as a novel suppository application for chronic intractable pain and other indications (“Tautomer Products”) in South Africa and the rest of Africa.
